These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24128004)

  • 1. WTP for a QALY and health states: More money for severer health states?
    Shiroiwa T; Igarashi A; Fukuda T; Ikeda S
    Cost Eff Resour Alloc; 2013; 11():22. PubMed ID: 24128004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.
    Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA
    Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Willingness to pay for QALY: perspectives and contexts in Japan.
    Igarashi A; Goto R; Yoneyama-Hirozane M
    J Med Econ; 2019 Oct; 22(10):1041-1046. PubMed ID: 31262236
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.
    Song HJ; Lee EK
    Medicine (Baltimore); 2018 Sep; 97(38):e12453. PubMed ID: 30235732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Willingness to pay for a quality-adjusted life-year: the individual perspective.
    Bobinac A; Van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2010 Dec; 13(8):1046-55. PubMed ID: 20825620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
    Nimdet K; Ngorsuraches S
    BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western Iran.
    Moradi N; Woldemichael A; Malekian P; Rotvandi DM; Rezaei S
    Cost Eff Resour Alloc; 2020; 18():47. PubMed ID: 33110399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the willingness to pay for a quality-adjusted life-year in the state of Penang, Malaysia.
    Shafie AA; Lim YW; Chua GN; Hassali MA
    Clinicoecon Outcomes Res; 2014; 6():473-81. PubMed ID: 25364267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of process utility: elucidating preferences for a non-invasive procedure to treat restenosis.
    Aviles-Blanco MV
    Health Econ Rev; 2021 Jul; 11(1):27. PubMed ID: 34297212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.
    Mavrodi A; Aletras V
    Value Health Reg Issues; 2020 Sep; 22():36-43. PubMed ID: 32731168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness to Pay for One Additional Quality Adjusted Life Year: A Population Based Survey from China.
    Ye Z; Abduhilil R; Huang J; Sun L
    Appl Health Econ Health Policy; 2022 Nov; 20(6):893-904. PubMed ID: 35934772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the value of curative therapies in oncology: a willingness-to-pay study in China.
    Huang L; Peng X; Sun L; Zhang D
    Cost Eff Resour Alloc; 2023 Jun; 21(1):37. PubMed ID: 37277820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diminishing willingness to pay per quality-adjusted life year: valuing acute foodborne illness.
    Haninger K; Hammitt JK
    Risk Anal; 2011 Sep; 31(9):1363-80. PubMed ID: 21488924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?
    Thavorncharoensap M; Teerawattananon Y; Natanant S; Kulpeng W; Yothasamut J; Werayingyong P
    Clinicoecon Outcomes Res; 2013; 5():29-36. PubMed ID: 23345984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monetary Value of Quality-Adjusted Life Years (QALY) among Patients with Cardiovascular Disease: a Willingness to Pay Study (WTP).
    Moradi N; Rashidian A; Rasekh HR; Olyaeemanesh A; Foroughi M; Mohammadi T
    Iran J Pharm Res; 2017; 16(2):823-833. PubMed ID: 28979338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
    Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
    PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity.
    Mavrodi A; Aletras V; Spanou A; Niakas D
    Pharmacoecon Open; 2017 Dec; 1(4):291-300. PubMed ID: 29441505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.
    Shiroiwa T; Fukuda T; Shimozuma K; Mouri M; Hagiwara Y; Kawahara T; Ohsumi S; Hozumi Y; Sagara Y; Ohashi Y; Mukai H
    BMC Cancer; 2017 Nov; 17(1):773. PubMed ID: 29149882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.